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AbstrACt
Introduction Cryptococcal meningitis is a neglected 
disease and an AIDS-defining illness, responsible for 15% 
of all AIDS-related deaths globally. In 2014, the estimated 
number of incident cryptococcal meningitis cases was 
223 100, with 73% of them occurring in Africa. Currently 
available data on the prevalence, incidence, aetiologies 
and mortality of cryptococcal meningitis across Africa are 
sparse and of limited quality. We propose to conduct the 
first systematic review to summarise the epidemiological 
data available on cryptococcal meningitis and its 
aetiological causes in Africa.
Methods and analysis We will search PubMed, MEDLINE, 
Excerpta Medica Database, ISI Web of Science, Africa 
Index Medicus, Cumulative Index to Nursing and Allied 
Health for studies on cryptococcal meningitis published 
between 1st January 1950 and 31st December 2017, 
involving adults and/or children residing in Africa. After 
study selection, full text paper acquisition and data 
extraction, we will use validated tools and checklists to 
assess the quality of reporting and risk of bias for each 
study. Heterogeneity across studies will be assessed 
using the χ2 test on Cochrane’s Q statistic and a random 
effect meta-analysis will be used to estimate the overall 
prevalence, incidence density and mortality of cryptococcal 
meningitis across studies with similar characteristics. This 
protocol is prepared and presented in accordance with the 
2015 Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses Protocols guidelines. Reporting of 
the results will be compliant with the Meta-Analysis Of 
Observational Studies in Epidemiology (MOOSE) guidelines. 
Ethics and dissemination There is no requirement 
for ethical approval since we will be using data from 
published studies. The final report will be published 
in a peer-reviewed journal and further presented at 
conferences. This study is expected to provide useful 
contextual estimates needed to inform treatment policies 
on the African continent and assess the impact of 
diagnostic and prevention strategies on the burden of 
cryptococcal meningitis in the post antiretroviral therapy 
era.
PrOsPErO registration number CRD42017081312.
IntrOduCtIOn 
The invasive fungal disease cryptococcal 
meningitis (CM) is caused by members of 
the genus Cryptococcus which belongs to the 
phylum Basidiomycota.1–3 The genus Crypto-
coccus, a polyphyletic fungi, has been known 
for over a century and now comprises at least 
100 species described, with only a few known 
to cause diseases.4–6 The first cases of crypto-
coccosis in humans and animals were reported 
in the late 19th century but their cumulative 
incidence increased in the 1900s.7–9 Cases of 
cryptococcosis started increasing in Africa in 
the period 1940–1960 and it is thought that 
this was a result of the emergence of HIV/
AIDS in the Congo River basin.10 However, 
no evidence is available from the literature, 
laboratory or clinical reports to prove this 
assumption.9 The HIV/AIDS epidemic raised 
the profile of the genus Cryptococcus from 
being an obscure yeast pathogen to becoming 
one of the most important fungal cause of 
morbidity and mortality worldwide.11–15 
CM is a neglected disease and is known to 
occur in individuals with immunosuppression 
as well as in apparently immunocompetent 
subjects. In 2014, it was estimated that glob-
ally 278 000 people had cryptococcal antige-
naemia per annum, with 73% of the 223 100 
incident CM cases occurring in sub-Saharan 
Africa (sSA).11 15 CM is responsible for 15% 
of all AIDS-related deaths globally and its 
strength and limitation of this study
 ► To the best of our knowledge, this will be the first 
systematic review summarising data on the epide-
miology of cryptococcal meningitis in Africa.
 ► We will use state-of-the-art statistical tools to pool 
prevalence, incidence and mortality data, and this 
will ensure the reliability and the validity of our 
results.
 ► Potential limitations of this review could be the small 
number of eligible studies due to the poor quality 
of data and the high heterogeneity across studies 
in terms of diagnostic procedures and standard of 
care. This will impact our overall estimates of the 
disease burden and its aetiologies and might ulti-
mately prevent us from performing a meta-analysis.
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mortality is thought to be higher in sSA.15 The majority 
of CM cases in sSA are caused by Cryptococcus neoformans 
sensu stricto (genotype AFLP1/VNI), although cases due 
to other species are on the rise.2 16
Currently available data on the prevalence, incidence 
and mortality of CM across Africa are sparse and of limited 
quality.12 13 17 The majority of discrepancies in African 
countries are undoubtedly attributable to the shortage 
of resources for surveillance and clinical studies.12 More 
accurate estimates are needed to inform treatment poli-
cies on the continent and assess the impact of diagnostic 
and prevention strategies on the burden of CM in the 
postantiretroviral therapy (ART) era. Here, we present 
a protocol for the systematic review of the epidemiology 
and the aetiologies of CM in Africa. This protocol is 
prepared and presented according to the 2015 Preferred 
Reporting Items for Systematic Reviews and Meta-Anal-
yses Protocols  guidelines.18
General objective
The objective of this study is to summarise data on the 
epidemiology and aetiologies of CM in Africa.
specific objectives
This review intends to:
i. Estimate the prevalence of CM in Africa and sum-
marise the changes in incidence density over time us-
ing data of studies published between 1950 and 2017.
ii. Estimate the mortality of patients diagnosed with CM 
in Africa using data from studies published between 
1950 and 2017.
iii. Determine the relative contribution of various 
Cryptococcus species to the burden of CM in Africa.
MEthOds
search strategy for the identification of relevant studies
A comprehensive literature search will be performed in 
PubMed, MEDLINE database, the Excerpta Medica Data-
base, the ISI Web of Science (Science Citation Index), 
the Africa Index Medicus and the Cumulative Index 
to Nursing and Allied Health to identify publications 
meeting the inclusion criteria. The literature search 
strategy is summarised in table 1. Following the search in 
databases, we will screen the reference lists of eligible arti-
cles and relevant reviews as well as conference proceed-
ings in order to identify additional sources of information. 
Finally, principal investigators of ongoing cohort studies 
and clinical trials will be contacted to request interim 
data relevant to our objectives, and a co-authorship will 
be offered as counterpart if they extract and supply the 
data. Search results will be compiled using the citation 
management software EndNote V.X6.0.1. The anticipated 
start date for this review is the 15th November 2017 and 
ending on the 30th June 2018.
Criteria for considering studies for the review
Inclusion criteria
We will include all the observational studies and clin-
ical trials conducted between the 1st January 1950 and 
31st December 2017, involving adults and/or children 
residing in Africa, and reporting the prevalence, the 
incidence and the mortality of CM or enough data to 
compute these estimates. Published data of studies will 
be considered without language restriction. For CM diag-
nosis, there should be at least one positive test on the 
cerebrospinal fluid (CSF) regardless of the blood sample 
result.
Table 1 Search strategy
Search Search terms and combinations
1 “Cryptococcus” OR “Cryptococcal” OR “Cryptococcosis” OR “Cryptococcus neoformans variety neoformans” 
OR “Cryptococcus neoformans variety grubii” OR “Cryptococcus neoformans variety gattii” OR “Cryptococcus 
neoformans” OR “Cryptococcus gattii” OR “Cryptococcus deneoformans” OR “Cryptococcus bacillisporus” OR 
“Cryptococcus deuterogattii” OR “Cryptococcus tetragattii” OR “Cryptococcus decagattii” OR “C. neoformans var. 
neoformans” OR “C. neoformans var. grubii” OR “C. neoformans var. gattii” OR “C. neoformans” OR “C. gattii” OR 
“C. deneoformans” OR “C. bacillisporus” OR “C. deuterogattii” OR “C. tetragattii” OR “C. decagattii”
2 “Meningitis”
3 “Mortality” OR “Death” OR “Fatality” OR “Prevalence” OR “Incidence” OR “Outcome” OR “Epidemiology” OR 
“Burden”
4 ((“Africa” OR “Africa*” OR “Algeria” OR “Angola” OR “Benin” OR “Botswana” OR “Burkina Faso” OR “Burundi” 
OR “Cape Verde” OR “Cameroon” OR “Central African Republic” OR “Chad” OR “Comoros” OR “Democratic 
Republic of Congo” OR “Congo” OR “Ivory Coast” OR “Djibouti” OR “Egypt” OR “Equatorial Guinea” OR “Eritrea” 
OR “Ethiopia” OR “Gabon” OR “Gambia” OR “Ghana” OR “Guinea” OR “Guinea-Bissau” OR “Kenya” OR “Lesotho” 
OR “Liberia” OR “Libya” OR “Madagascar” OR “Malawi” OR “Mali” OR “Mauritania” OR “Mauritius” OR “Morocco” 
OR “Mozambique” OR “Namibia” OR “Niger” OR “Nigeria” OR “Rwanda” OR “Sao Tome and Principe” OR 
“Senegal” OR “Seychelles” OR “Sierra Leone” OR “Somalia” OR “South Africa” OR “South Sudan” OR “Sudan” 
OR “Swaziland” OR “Tanzania” OR “Togo” OR “Tunisia’ OR “Uganda” OR “Zambia” OR “Zimbabwe”) NOT 
(“Aspergillus” OR “pig*” OR “Papua”))
5 #1 AND #2 AND #3 AND #4
6 Filters: Publication date from 1950/01/01 to 2017/12/31; Humans
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Exclusion criteria
i. Studies conducted outside the African continent.
ii. Studies with small sample size (less than 30 partici-
pants), letters, commentaries, narrative reviews and 
editorials.
iii. Studies lacking primary data or with incomplete 
methods description.
iv. Duplicates (for studies leading to more than one 
publication, only the most comprehensive report in-
cluding the largest sample size will be considered).
v. Studies not involving human participants (if any).
vi. Studies in which the diagnostic criteria for CM are 
unclear or not scientifically acceptable (with no re-
port/record of a test performed on the CSF sample).
selection of studies for inclusion in the review
Titles and abstracts of studies identified by our search 
strategy will be screened independently for their eligibility 
by two members of the research team (TKN and JKT). 
Full texts of articles deemed eligible will be retrieved and 
further assessed for inclusion by the same investigators. 
A screening guide will be developed to ensure consis-
tency of the screening method applied by both assessors. 
Any disagreement will be resolved by discussion and 
consensus. If the latter is not reached, arbitration will 
be sought from a third member of the team (FH). The 
inter-rater agreement for the selection of studies will be 
assessed using a non-weighted Cohen’s kappa statistic.19 20
Appraisal of the quality of reporting and the risk of bias
The quality of reporting of the studies included will be 
assessed using either the Strengthening the Reporting of 
Observational Studies in Epidemiology or the Consoli-
dated Standards of Reporting Trials checklist depending 
on the nature of the study (observational study or clinical 
trial).21 22
The 10-item risk of bias tool for prevalence studies 
developed by Hoy et al,23 will be used to assess the meth-
odological quality and the risk of bias for all the studies 
included using the full text publications. Risk of bias and 
quality of reporting scores will be presented in a table and 
inter-rater agreement will be assessed using a weighted 
Cohen’s kappa statistic.24 25
data extraction
A standardised data extraction sheet will be used to collect 
information on:
 ► Study identification: first author name, year of publi-
cation, year of participants’ inclusion, country, type of 
publication, language of publication (full text).
 ► Study characteristics: study design (cross-sectional, 
cohort, case-control, clinical trial), setting (hospital, 
population), period of recruitment, sample size, 
mean or median age, age range, proportions of 
male participants, proportion of patients on anti-
fungal prophylaxis (if any), proportion of HIV-nega-
tive participants (if any), proportion of HIV-positive 
patients under ART (if any), number of patients with 
CM, diagnostic criteria for CM (India ink staining, 
culture, genotyping, detection of cryptococcal 
antigen in blood, detection of cryptococcal antigen 
in the CSF, lateral flow assay in whole blood, plasma 
or serum), treatment protocol used in patients diag-
nosed with CM (drug, route of administration, dura-
tion of treatment), duration of follow-up for cohort 
studies. 
 ► Epidemiological estimates: prevalence, incidence and 
mortality of CM. Whenever these estimates are not 
readily available or computable using primary data 
in the publication, the corresponding author will be 
contacted to request the missing information.
 ► Genotypic results (proportion of cases caused by each 
Cryptococcus species).
data analysis and reporting
Data will be analysed using the metaprop command 
provided with the software STATA (V.13, StataCorp).26 
Heterogeneity will be evaluated by the χ2 test on 
Cochrane’s Q statistic27 and quantified using I² values, 
assuming that I² values of 25%, 50% and 75%, repre-
sent low, medium and high heterogeneity, respectively.28 
Study-specific estimates will be determined from the point 
estimate and the appropriate denominators, assuming a 
binominal distribution. Then, the study-specific estimates 
will be pooled through a random effects meta-analysis to 
obtain an overall summary estimate of the prevalence, 
incidence and mortality of CM across studies, after stabi-
lising the variance of individual studies using the Free-
man-Tukey double arcsine transformation.29 30 Where 
substantial heterogeneity will be detected, a subgroup 
analysis will be performed to detect its possible sources. 
Specific subgroup analyses by period of recruitment or by 
proportion of patients under ART will also be performed 
to explore how specific public health interventions 
influence the prevalence, the incidence density and the 
mortality of CM over time. Visual analysis of funnel plot 
and Egger’s test will be done to detect small study effect.31 
All tests will be two-sided, and statistical significance will 
be defined as p<0.05.
The results of this systematic review will be reported 
according to the Meta-Analysis Of Observational Studies 
in Epidemiology (MOOSE) guidelines.32 The study selec-
tion process will be summarised using a flow diagram. 
Reasons for study exclusion will be described. Quantita-
tive data will be presented in summary tables and forest 
plots where appropriate.
Ethics and dissemination
This systematic review will be based on published data 
and will therefore not require a specific ethics clearance. 
The results will be published in peer-reviewed journals 
and further presented at conferences. They will also be 
submitted to relevant health authorities. The review will 
be updated regularly at 5-year interval as new publications 
become available.
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Patient and public involvement
This systematic review will use published scientific data 
and will not involve patients or members of the public.
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